Treatment of the obsessive-compulsive and bipolar disorders comorbidity: pharmacodynamic and pharmacokinetic evaluation

References

• American psychiatric association committee on nomenclature and statistics. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Press; 2014.
   Google Scholar
• Lim M, Park DY, Kwon JS, et al. Prevalence and clinical characteristics of obsessive-compulsive symptoms associated with atypical antipsychotics. J Clin Psychopharmacol. 2007;27(6):712–713. PMID: 18004145.
   Google Scholar
• Koran LM, Ringold AL, Elliott MA. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2000;61(7):514–517. PMID: 10937610.
   Google Scholar
• Angst J, Gamma A, Endrass J, et al. Obsessive-compulsive syndromes and disorders: significance of comorbidity with bipolar and anxiety syndromes. Eur Arch Psychiatry Clin Neurosci. 2005;255(1):65–71. PMID: 15711895.
   Google Scholar
• Mucci F, Toni C, Favaretto E, et al. Obsessive-compulsive disorder with comorbid bipolar disorders: clinical features and treatment implications. Curr Med Chem. 2018;25(41):5722–5730. PMID: 29119914.
   Google Scholar
• Dell’Osso B, Buoli M, Bortolussi S, et al. Patterns of Axis I comorbidity in relation to age in patients with bipolar disorder: a cross-sectional analysis. J Affect Disord. 2011;130(1–2):318–322. PMID: 21074273.
   Google Scholar
• Amerio A, Odone A, CC L, et al. Diagnostic validity of comorbid bipolar disorder and obsessive-compulsive disorder: a systematic review. Acta Psychiatr Scand . 2014;129(5):343–358. PMID: 24506190.
   Google Scholar
• Kazhungil F, Mohandas E. Management of obsessive-compulsive disorder comorbid with bipolar disorder. Indian J Psychiatry. 2016;58(3):259–269. PMID: 28066002.
   Google Scholar
• Marazziti D. Treatment of obsessive-compulsive disorder. In: Marazziti D, editor. clinical psychopharmacotherapy. Rome: giovanni Fioriti Editore. 2018. p. 141–152).
   Google Scholar
• Rybakowski JK. Two generations of mood stabilizers. Int J Neuropsychopharmacol. 2007;10(5):709–711. PMID: 17982754.
   Google Scholar
• Rybakowski JK. Meaningful aspects of the term ‘mood stabilizer’. Bipolar Disord. 2018;20(4):391–392. PMID: 29327794.
   Google Scholar
• Dold M, Aigner M, Lanzenberger R, et al. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials. Int J Neuropsychopharmacol. 2013;16(3):557–574. PMID: 22932229.
   Google Scholar
• Amerio A, Odone A, Ghaemi SN. Aripiprazole augmentation in treating comorbid bipolar disorder and obsessive-compulsive disorder: A systematic review. J Affect Disord. 2019;249:15–19. PMID: 30743017.
   Google Scholar
• Veale D, Miles S, Smallcombe N, et al. Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis. BMC Psychiatry. 2014;14:317. PMID: 25432131.
   Google Scholar
• Hussain A, Dar MA, Wani RA, et al. Role of lamotrigine augmentation in treatment-resistant obsessive compulsive disorder: a retrospective case review from South Asia. Indian J Psychol Med. 2015;37(2):154–158. PMID: 25969599.
   Google Scholar
• Khalkhali M, Aram S, Zarrabi H, et al. Lamotrigine augmentation versus placebo in serotonin reuptake inhibitors-resistant obsessive-compulsive disorder: a randomized controlled trial. Iran J Psychiatry. 2016;11(2):104–114. PMID: 27437007.
   Google Scholar
• Sharma V, Doobay M. Lamotrigine-induced obsessive-compulsive disorder in patients with bipolar disorder. CNS Spectr. 2018;8:1–5. PMID: 30086812.
   Google Scholar
• Marazziti D, Avella MT, Basile L, et al. Pharmacokinetics of serotonergic drugs: focus on OCD. Expert Opin Drug Metab Toxicol. 2019. PMID: 30793987.
   Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1–34. PMID: 19631507.
   Google Scholar
• Finley PR, Warner MD, Peabody CA. Clinical relevance of drug interations with lithium. Clin Pharmacokinet. 1995;29:172–191. PMID: 8521679
   Google Scholar
• Sproule BA, Naranjo CA, Brenmer KE, et al. Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. Clin Pharmacokinet. 1997;33(6):454–471. PMID: 9435993
   Google Scholar
• Noveske FG, Hahn KR, Flynn R,J, et al. Possible toxicity of combined fluoxetine and lithium [letter]. Am J Psychiatry. 1989;146:1515. PMID: 2510522
   Google Scholar
• Austin LS, Arana GW, Melvin JA, et al. Toxicity resulting from lithium augmentation of antidepressant treatment in elderly patients. J Clin Psychiatry. 1990;150:344–345. PMID: 2380160
   Google Scholar
• Fava M, Rosenbaum JF, McGrath PJ, et al. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double blind, controlled study. Am J Psychiatry. 1994;151:1372–1374. PMID: 8067495
   Google Scholar
• Baumannn P, Souche A, Montaldi S, et al. A double-blind, placebo- controlled study of citalopram with and without lithium in the treatment of therapy resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation. J Clin Psychopharmacol. 1996;16:307–314. PMID: 8835706
   Google Scholar
• Fagiolini A, Buysse DJ, Frank E, et al. Tolerability of combined treatment with lithium and paroxetine in patients with bipolar disorder and depression. J Clin Psychopharmacol. 2001;21(5):474–478. PMID: 11593071
   Google Scholar
• Apsleoff G, Wilner KD, von Deutsch DA, et al. Sertraline does not alter steady-state concentrations or renal clearance of lithium in healty volonteers. J Clin Pharmacol. 1992;32:643–646). PMID: 1640004
   Google Scholar
• Miljkovic BR, Pokrajac M, Timotijevic I, et al. The influence of lithium on fluvoxamine efficacy and pharmacokinetics in depressed patients on combined fluvoxamine-lithium therapy. Int Clin Psychopharmacol. 1997;12:207–212. PMID: 9347381
   Google Scholar
• Tondo L, Mannu P, Silvetti F, et al. Fluoxetine augmentation in bipolar disorder patients on maintenance lithium treatment. Int J Psychiatry Clin Pract. 1997;1:203–206. PMID: 24940836
   Google Scholar
• Troy SM, Parker VD, Hicks DR, et al. Pharmacokinetic interactions between multiple-dose venlafaxine and single dose lithium. J Clin Pharmacol. 1996;36:175–181. PMID: 8852394
   Google Scholar
• Januel D, Poirier MF, D’alche-Biree F, et al. Multicenter double-blind randomized parallel-group clinical trial of efficacy of the combination clomipramine (150 mg/day) plus lithium carbonate (750 mg/day) versus clomipramine (150 mg/day) plus placebo in the treatment of unipolar major depression. J Affect Disord. 2003 Sep;76(1–3):191–200. PMID: 12943949
   Google Scholar
• Spina E, Pisani F, de Leon J. Clinically significant pharmacokinetic drug interactions of antiepileptic drugs with new antidepressants and new antipsychotics. Pharmacol Res. 2016;106:72–86. PMID: 26896788.
   Google Scholar
• Sovner R, Davis JM. A potential drug interaction between fluoxetine and valproic acid. J Clin Psychopharmacol. 1991;11(6):389. PMID: 1770158.
   Google Scholar
• Berigan T, Harazin J. A sertraline/valproic acid drug interaction: case Reports. Int J Psychiatry Clin Pract. 1999;3(4):287–288. PMID: 24921233.
   Google Scholar
• Fehr C, Grunder G, Hiemke C, et al. Increase in serum clomipramine concentrations caused by valproate. J Clin Psychopharmacol. 2000;20(4):493–494. PMID: 10917416.
   Google Scholar
• Dean L. Carbamazepine Therapy and HLA Genotype. In: Pratt V, McLeod H, Rubinstein W, et al. editors. Medical Genetics Summaries. Bethesda (MD); 2012.
   Google Scholar
• Spina E, Avenoso A, Pollicino AM, et al. Carbamazepine coadministration with fluoxetine or fluvoxamine. Ther Drug Monit. 1993;15(3):247–250. PMID: 8333006
   Google Scholar
• Grimsley SR, Jann MW, Carter JG, et al. Increased carbamazepine plasma concentrations after fluoxetine coadministration. Clin Pharmacol Ther. 1991;50(1):10–15. PMID: 1855347.
   Google Scholar
• Møller SE, Larsen F, Khan AZ, et al. Lack of effect of citalopram on the steady-state pharmacokinetics of carbamazepine in healthy male subjects. J Clin Psychopharmacol. 2001;21(5):493–499. PMID: 11593075.
   Google Scholar
• Andersen BB, Mikkelsen M, Vesterager A, et al. No influence of the antidepressant paroxetine on carbamazepine, valproate and phenytoin. Epilepsy Res. 1991;10(2):201–204. PMID: 1840138.
   Google Scholar
• Rapeport WG, Williams SA, Muirhead DC, et al. Absence of a sertraline-mediated effect on the pharmacokinetics and pharmacodynamics of carbamazepine. J Clin Psychiatry. 1996;57(Suppl 1):20–23. PMID: 8617707
   Google Scholar
• Brunton LL, Knollmann BC, Hilal-Dandan R, et al. Goodman & Gilman’s the pharmacological basis of therapeutics. 2018. McGraw Hill Medical. 13th edition. https://www.ncbi.nlm.nih.gov/nlmcatalog/101708739.
   Google Scholar
• May TW, Korn-Merker E, Rambeck B. Clinical pharmacokinetics of oxcarbazepine. Clin Pharmacokinet. 2003;42(12):1023–1042. PMID: 12959634.
   Google Scholar
• Dardis C, Omoregie E, Ly V. Fatal serotonin syndrome precipitated by oxcarbazepine in a patient using an selective serotonin reuptake inhibitor. Neurologist. 2012;18(4):204–205. PMID: 22735246.
   Google Scholar
• Leinonen E, Lepola U, Koponen H. Substituting carbamazepine with oxcarbazepine increases citalopram levels. A report on two cases. Pharmacopsychiatry. 1996;29(4):156–158. PMID: 8858715.
   Google Scholar
• Reimers A, Skogvoll E, Sund JK, et al. Drug interactions between lamotrigine and psychoactive drugs: evidence from a therapeutic drug monitoring service. J Clin Psychopharmacol. 2005;25(4):342–348. PMID: 16012277.
   Google Scholar
• Christensen J, Sandgaard AP, Sidenius P, et al. Lack of interaction between sertraline and lamotrigine in psychiatric patients: a retrospective study. Pharmacopsychiatry. 2012;45(3):119–121. PMID: 22426846.
   Google Scholar
• Kudo S, Ishizaki T. Pharmacokinetics of haloperidol: an update. Clin Pharmacokinet. 1999;37(6):435–456. PMID: 10628896..
   Google Scholar
• Vandel S, Bertschy G, Baumann P, et al. Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. Pharmacol Res. 1995;31(6):347–353. PMID: 8685072.
   Google Scholar
• Yasui-Furukori N, Kondo T, Mihara K, et al. Fluvoxamine dose-dependent interaction with haloperidol and the effects on negative symptoms in schizophrenia. Psychopharmacology (Berl). 2004;171(2):223–227. PMID: 12955290.
   Google Scholar
• Tate JL. Extrapyramidal symptoms in a patient taking haloperidol and fluoxetine. Am J Psychiatry. 1989;146(3):399–400. PMID: 2784039.
   Google Scholar
• Lee MS, Kim YK, Lee SK, et al. A double-blind study of adjunctive sertraline in haloperidol-stabilized patients with chronic schizophrenia. J Clin Psychopharmacol. 1998;18(5):399–403. PMID: 9790158.
   Google Scholar
• Gram LF, Overo KF. Drug interaction: inhibitory effect of neuroleptics on metabolism of tricyclic antidepressants in man. Br Med J. 1972;1(5798):463–465. PMID: 5008054.
   Google Scholar
• Desta Z, Soukhova N, Flockhart DA. In vitro inhibition of pimozide N-dealkylation by selective serotonin reuptake inhibitors and azithromycin. J Clin Psychopharmacol. 2002;22(2):162–168. PMID: 11910261.
   Google Scholar
• Ahmed I, Dagincourt PG, Miller LG, et al. Possible interaction between fluoxetine and pimozide causing sinus bradycardia. Can J Psychiatry. 1993;38(1):62–63. PMID: 8448725.
   Google Scholar
• Horrigan JP, Barnhill LJ. Paroxetine-pimozide drug interaction. J Am Acad Child Adolesc Psychiatry. 1994;33(7):1060–1061. PMID: 7961347.
   Google Scholar
• Alderman J. Coadministration of sertraline with cisapride or pimozide: an open-label, nonrandomized examination of pharmacokinetics and corrected QT intervals in healthy adult volunteers. Clin Ther. 2005;27(7):1050–1063. PMID: 16154484.
   Google Scholar
• US Food and Drug Administration. Orap (pimozide) 1 and 2 mg tablets. 2009. Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/Safety-RelatedDrugLabelingChanges/ucm153643.htm
   Google Scholar
• Glassman AH, Bigger JT Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry. 2001;158(11):1774–1782. PMID: 11691681.
   Google Scholar
• Heykants J, Huang ML, Mannens G, et al. The pharmacokinetics of risperidone in humans: a summary. J Clin Psychiatry. 1994;55(Suppl):3–17. PMID: 7520903.
   Google Scholar
• Spina E, Avenoso A, Scordo MG, et al. Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction. J Clin Psychopharmacol. 2002;22(4):419–423. PMID: 12172343.
   Google Scholar
• Saito M, Yasui-Furukori N, Nakagami T, et al. Dose-dependent interaction of paroxetine with risperidone in schizophrenic patients. J Clin Psychopharmacol. 2005;25(6):527–532. PMID: 16282832.
   Google Scholar
• Spina E, D’Arrigo C, Migliardi G, et al. Plasma risperidone concentrations during combined treatment with sertraline. Ther Drug Monit. 2004;26(4):386–390. PMID: 15257068.
   Google Scholar
• D’Arrigo C, Migliardi G, Santoro V, et al. Effect of fluvoxamine on plasma risperidone concentrations in patients with schizophrenia. Pharmacol Res. 2005;52(6):497–501. PMID: 16226034.
   Google Scholar
• McDougle CJ, Epperson CN, Pelton GH, et al. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry. 2000;57(8):794–801. PMID: 10920469.
   Google Scholar
• Ravizza L, Barzega G, Bellino S, et al. Therapeutic effect and safety of adjunctive risperidone in refractory obsessive-compulsive disorder (OCD). Psychopharmacol Bull. 1996;32(4):677–682. PMID: 8993091.
   Google Scholar
• Nikolaou KN, Gournellis R, Michopoulos I, et al. Neurotoxic syndrome induced by clomipramine plus risperidone in a patient with autistic spectrum disorder: serotonin or neuroleptic malignant syndrome? Ann Gen Psychiatry. 2015;14:38. PMID: 26583039.
   Google Scholar
• Nemoto K, Mihara K, Nakamura A, et al. Effects of paroxetine on plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia. Ther Drug Monit. 2012;34(2):188–192. PMID: 22377745.
   Google Scholar
• Waade RB, Christensen H, Rudberg I, et al. Influence of comedication on serum concentrations of aripiprazole and dehydroaripiprazole. Ther Drug Monit. 2009;31(2):233–238. PMID: 19142178.
   Google Scholar
• Delle Chiaie R, Scarciglia P, Pasquini M, et al. Aripiprazole augmentation in patients with resistant obsessive compulsive disorder: a pilot study. Clin Pract Epidemiol Ment Health. 2011;7:107–111. PMID: 21686322.
   Google Scholar
• Potkin SG, Thyrum PT, Alva G, et al. Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine. J Clin Psychopharmacol. 2002;22(2):174–182. PMID: 11910263.
   Google Scholar
• Castberg I, Skogvoll E, Spigset O. Quetiapine and drug interactions: evidence from a routine therapeutic drug monitoring service. J Clin Psychiatry. 2007;68(10):1540–1545. PMID: 17960969.
   Google Scholar
• Matsumoto R, Kitabayashi Y, Nakatomi Y, et al. Neuroleptic malignant syndrome induced by quetiapine and fluvoxamine. Am J Psychiatry. 2005;162(4):812. PMID: 15800166.
   Google Scholar
• Marlowe K, Schirgel D. Quetiapine and citalopram: aetiological significances in serotonin syndrome. N Z Med J. 2006;119(1237):U2058. PMID: 16862204.
   Google Scholar
• Gossen D, de Suray JM, Vandenhende F, et al. Influence of fluoxetine on olanzapine pharmacokinetics. AAPS PharmSci. 2002;4(2):E11. PMID: 12102620.
   Google Scholar
• Weigmann H, Gerek S, Zeisig A, et al. Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit. 2001;23(4):410–413. PMID: 11477325.
   Google Scholar
• Hiemke C, Peled A, Jabarin M, et al. Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects. J Clin Psychopharmacol. 2002;22(5):502–506. PMID: 12352274.
   Google Scholar
• Davies SJ, Mulsant BH, Flint AJ, et al. the impact of sertraline co-administration on the pharmacokinetics of Olanzapine: a population pharmacokinetic analysis of the STOP-PD. Clin Pharmacokinet. 2015;54(11):1161–1168. PMID: 25971243.
   Google Scholar
• Deshauer D, Albuquerque J, Alda M, et al. Seizures caused by possible interaction between olanzapine and clomipramine. J Clin Psychopharmacol. 2000;20(2):283–284. PMID: 10770480.
   Google Scholar
• Verre M, Bossio F, Mammone A, et al. Serotonin syndrome caused by olanzapine and clomipramine. Minerva Anestesiol. 2008;74(1–2):41–45. PMID: 18004234.
   Google Scholar
• Cohen WJ, Cohen NH. Lithium carbonate, haloperidol and irreversible brain damage. JAMA. 1974;230:1283–1287. PMID: 4479505
   Google Scholar
• Coffey CE, Ross DR. Treatment of lithium/neuroleptic neurotoxicity during lithium maintenance. Am J Psychiatry. 1980;137:736–737. PMID: 7377401
   Google Scholar
• Jefferson JW, Greist JH. Haloperidol and lithium: their combined useand the issueof their compatibility; in Ayd (Ed) haloperidol update: 1958-1980. p. 73. (Ayd Medical Communications, Baltimore 1980).
   Google Scholar
• Baastrup PC, Hollnagel P, Sorensen R, et al. Adverse reactions in treatment with lithium carbonate and haloperidol. JAMA. 1976;236(23):2645–2646. PMID: 1036539
   Google Scholar
• Thomas CJ. Brain damage with lithium/haloperidol. Br J Psychiatry. 1979;134:552. PMID: 476365
   Google Scholar
• Amdisen A. Lithium and drug interactions. Drugs. 1982;24(2):133–139. PMID: 6126349
   Google Scholar
• Loudon JB, Waring H. Toxic reactions to lithium and haloperidol. Lancet. 1976;2(7994):1088. PMID: 62931
   Google Scholar
• Kessel JB, Verghese C, Simpson GM. Neurotoxicity related to lithium and neuroleptic combinations? A retrospective review. J Psychiatry Neurosci. 1992;17(1):28–30. PMID: 1349826
   Google Scholar
• Lassen E, Vestergaard P, Thomsen K. Renal function of patients in long-term treatment with lithium citrate alone or in combination with neuroleptics and antidepressant drugs. Arch Cen Psychiatry. 1986;43:481–482. PMID: 2870695
   Google Scholar
• Goldman SA. Lithium and neuroleptics in combination: is there enhancement of neurotoxicity leading to permanent sequelae? J Clin Pharmacol. 1996;36(10):951–962. PMID: 8930783
   Google Scholar
• Goldney RD, Spence ND. Safety of the combination of lithium and neuroleptic drugs. Am J Psychiatry. 1986;143(7):882–884. PMID: 2872825
   Google Scholar
• Kahn EM, Schulz SC, Perel JM, et al. Change in haloperidol level due to carbamazepine–a complicating factor in combined medication for schizophrenia. J Clin Psychopharmacol. 1990;10(1):54–57. PMID: 2106534.
   Google Scholar
• Hesslinger B, Normann C, Langosch JM, et al. Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients. J Clin Psychopharmacol. 1999;19(4):310–315. PMID: 10440457.
   Google Scholar
• Boulton DW, Kollia GD, Mallikaarjun S, et al. Lack of a pharmacokinetic drug-drug interaction between lithium and valproate when co-administered with aripiprazole. J Clin Pharm Ther. 2012;37(5):565–570. PMID: 22943745.
   Google Scholar
• Citrome L, Macher JP, Salazar DE, et al. Pharmacokinetics of aripiprazole and concomitant carbamazepine. J Clin Psychopharmacol. 2007;27(3):279–283. PMID: 17502775.
   Google Scholar
• Schoretsanitis G, Haen E, Grunder G, et al. Pharmacokinetic drug-drug interactions of mood stabilizers and risperidone in patients under combined treatment. J Clin Psychopharmacol. 2016;36(6):554–561. PMID: 27376639.
   Google Scholar
• Demling JH, Huang ML, Remmerie B, et al. Pharmacokinetics and safety of combination therapy with lithium and risperidone. Pharmacopsychiatry. 2006;39(06):230–231. PMID: 17124646.
   Google Scholar
• Winter HR, DeVane CL, Figueroa C, et al. Open-label steady-state pharmacokinetic drug interaction study on co-administered quetiapine fumarate and divalproex sodium in patients with schizophrenia, schizoaffective disorder, or bipolar disorder. Hum Psychopharmacol. 2007;22(7):469–476. PMID: 17729385.
   Google Scholar
• Aichhorn W, Marksteiner J, Walch T, et al. Influence of age, gender, body weight and valproate comedication on quetiapine plasma concentrations. Int Clin Psychopharmacol. 2006;21(2):81–85. PMID: 16421458.
   Google Scholar
• Andersson ML, Bjorkhem-Bergman L, Lindh JD. Possible drug-drug interaction between quetiapine and lamotrigine–evidence from a Swedish TDM database. Br J Clin Pharmacol. 2011;72(1):153–156. PMID: 21651616.
   Google Scholar
• Fitzgerald BJ, Okos AJ. Elevation of carbamazepine-10,11-epoxide by quetiapine. Pharmacotherapy. 2002;22(11):1500–1503. PMID: 12432977.
   Google Scholar
• Spina E, D’Arrigo C, Muscatello V, et al. Effect of valproate on olanzapine plasma concentrations in patients with bipolar or schizoaffective disorder. Ther Drug. 2009;31(6):758–763. PMID: 19865002.
   Google Scholar
• Spina E, D’Arrigo C, Migliardi G, et al. Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder. Ther Drug Monit. 2006 Oct;28(5):599–602. PMID: 17038872.
   Google Scholar
• Bergemann N, Frick A, Parzer P, et al. Olanzapine plasma concentration, average daily dose, and interaction with co-medication in schizophrenic patients. Pharmacopsychiatry. 2004;37(2):63–68. PMID: 15048613.
   Google Scholar
• Linnet K, Olesen OV. Free and glucuronidated olanzapine serum concentrations in psychiatric patients: influence of carbamazepine comedication. Ther Drug Monit. 2002;24(4):512–517. PMID: 12142636.
   Google Scholar
• Lucas RA, Gilfillan DJ, Bergstrom RF. A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism. Eur J Clin Pharmacol. 1998;54(8):639–643. PMID: 9860152.
   Google Scholar
• Albert U, Carmassi C, Cosci F, et al. Role and clinical implications of atypical antipsychotics in anxiety disorders, obsessive-compulsive disorder, trauma-related, and somatic symptom disorders: a systematized review. Int Clin Psychopharmacol. 2016;31(5):249-58. doi:10.1097/YIC.0000000000000127. PMID: 26974213.
   Google Scholar